Eli Lilly and Company (India) Pvt. Ltd. announced the launch of Humalog 200U/mL KwikPen (insulin lispro 200U/mL), a pre-filled pen containing a concentrated formulation of Lilly's rapid-acting insulin Humalog (insulin lispro).
Over time, some patients may require dosage increase for improved glycemic control. This also leads to increase in number of pens being used. Humalog 200 U/mL KwikPen offers physicians an alternative that allows patients to inject 50% less insulin volume.
Often the transition to a more intensified mealtime insulin therapy is difficult for patients. Humalog 200 U/mL KwikPen is another option that may help make mealtime insulin therapy more convenient.
Humalog 200U/mL KwikPen contains concentrated 200U/mL rapid-acting insulin and delivers the same units of insulin in half the volume as 100U/mL mealtime insulin pens. It holds twice as many insulin units, hence it lasts longer and allow fewer pen changes every month.
With no dose conversions required it can be dialed in one-unit increments to a maximum of 60units per injection.“Patients may require dosage increase over time for better glycemic control. Humalog 200U/mL KwikPen provides physicians’ a new prescription option for their patients.
Fewer pen changes per month may help people who require higher daily doses of mealtime insulin making it a convenient option for patients who lead busy lives.” Said Edgard Olaizola, managing director, Eli Lilly and Company (India) Pvt. Ltd. “Lilly is committed to bringing innovative products to India.”
“Since 1923, the needs of patients have continually inspired Lilly to innovate and introduce strategies for better outcomes. While efficacy and safety are critical, simplicity and ease of use are just as important.” Said Tarun Puri, medical director, Eli Lilly & Company (India) Pvt Ltd. Humalog 200U/mL KwikPen is bioequivalent to Humalog 100U/mL; therefore, similar efficacy and safety as Humalog 100U/mL.
Eli Lilly and Company (India) Pvt. Ltd. (Lilly), headquartered in Gurgaon, is a wholly owned subsidiary of Eli Lilly and Company, a global biopharmaceutical company headquartered in Indianapolis, USA. Since its inception in India in 1993, Eli Lilly and Company (India) Pvt. Ltd. Has been committed to developing and marketing pharmaceutical products to treat diabetes, lung cancer, osteoporosis and growth-hormone deficiency.